Alzheimer’s Small-Molecule Therapy Shows Promise in Mice and Early Human Trial
A small-molecule therapy, VG-3927, targeting microglial TREM2 signaling showed neuroprotective effects in preclinical studies for Alzheimer's disease and was well tolerated in a Phase I trial.